Cancers, Vol. 11, Pages 1909: A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention

In this study, we tested whether vaccinations with DCs, loaded with a PD-L1 immunogen (PDL1-Vax), are able to induce anti-PD-L1 immune responses. We found that DCs loaded with PDL1-Vax induced anti-PD-L1 antibody and T cell responses in immunized mice and that PD-L1-specific CTLs had cytolytic activities against PD-L1+ tumor cells. We demonstrated that vaccination with PDL1-Vax DCs potently inhibited the growth of PD-L1+ tumor cells. In summary, this study demonstrates for the first time the principle and feasibility of DC vaccination (PDL1-Vax) to actively induce anti-PD-L1 antibody and T cell responses capable of inhibiting PD-L1+ tumor growth. This novel anti-PD-L1 vaccination strategy could be used for cancer treatment and prevention.

Source: Cancers - November 30, 2019 Category: Cancer & Oncology Authors: Jie Chen Hui Liu Tiffany Jehng Yanqing Li Zhoushi Chen Kuan-Der Lee Hsieh-Tsung Shen Lindsey Jones Xue F. Huang Si-Yi Chen Tags: Article Source Type: research